When did NewAmsterdam Pharma Company report Q4 2024 earnings?

NewAmsterdam Pharma Company (NAMS) reported Q4 2024 earnings on February 26, 2025 before market open.

What were NewAmsterdam Pharma Company's Q4 2024 revenue and EPS?

NewAmsterdam Pharma Company reported revenue of $13.2M and eps of $-0.95 for Q4 2024.

Did NewAmsterdam Pharma Company beat estimates in Q4 2024?

Revenue beat the consensus estimate of $1.8M by $11.5M. EPS missed the consensus estimate of $-0.48 by $0.47.

Where can I find NewAmsterdam Pharma Company's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-027339) directly on SEC EDGAR. The filing index links above go to sec.gov.

NewAmsterdam Pharma Company NAMS Q4 2024 Annual earnings

Reported February 26, 2025 · Before market open

Revenue$13.2MBeat by $11.5M

EPS-$0.95Miss by $0.47

Revenue estimate$1.8M

EPS estimate-$0.48

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$1.9M

EPS estimate-$0.48

Financials

Q4 2024

Income statement

See full

Revenue$12.8M+1,491%

Operating income-$43.2M+15.4%

Net income-$92.2M-86.2%

EPS (diluted)-$0.95-58.3%

Balance sheet

See full

Cash & equivalents$771.7M+127%

Total debt$448.0K+647%

Total equity$757.5M+163%

Total assets$864.6M+149%

Cash flow

See full

Operating cash flow-$37.5M-13.3%

CapEx$3.0K0.0%

Free cash flow-$37.5M-13.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.75B+174%

Enterprise value$1.98B+198%

P/S60.4×-11.0×

Profitability

See full

Operating margin-386.9%-160pp

Net margin-530.3%-194pp

FCF margin-349.5%-138pp

Returns & leverage

See full

Return on equity-46.2%-2.7pp

Debt / equity0×0.0×

Current ratio8.1×+1.1×

Versus estimates

Revenue

Q1 2026$3.0MBeat by $1.3M Q4 2025$32.0KMiss by $1.2M Q3 2025$348.0KMiss by $2.1M Q2 2025$22.4MBeat by $18.9M Q1 2025$3.2MBeat by $1.8M

Q4 2024$13.2MBeat by $11.5M

Diluted EPS

Q1 2026-$0.40Beat by $0.06 Q4 2025-$0.63Miss by $0.23 Q3 2025-$0.41Miss by $0.03 Q2 2025-$0.15Beat by $0.37 Q1 2025-$0.49Miss by $0.04

Q4 2024-$0.95Miss by $0.47

Ask the moment NewAmsterdam Pharma Company reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did NewAmsterdam Pharma Company report Q4 2024 earnings?: NewAmsterdam Pharma Company (NAMS) reported Q4 2024 earnings on February 26, 2025 before market open.
What were NewAmsterdam Pharma Company's Q4 2024 revenue and EPS?: NewAmsterdam Pharma Company reported revenue of $13.2M and eps of $-0.95 for Q4 2024.
Did NewAmsterdam Pharma Company beat estimates in Q4 2024?: Revenue beat the consensus estimate of $1.8M by $11.5M. EPS missed the consensus estimate of $-0.48 by $0.47.
Where can I find NewAmsterdam Pharma Company's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-027339) directly on SEC EDGAR. The filing index links above go to sec.gov.